Brivanib Alaninate is primarily used in the field of oncology as a targeted therapy for cancer treatment. It functions as a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR), which are critical pathways in tumor angiogenesis and growth. By blocking these receptors, it helps to cut off the blood supply to tumors, thereby inhibiting their proliferation and spread. This compound has been investigated in clinical trials for the treatment of various cancers, including hepatocellular carcinoma (HCC) and colorectal cancer. Its application is particularly significant in cases where traditional chemotherapy or other targeted therapies have proven ineffective. The drug is administered orally, offering a convenient treatment option for patients. Research continues to explore its efficacy in combination with other anticancer agents to enhance therapeutic outcomes.